Altimmune, Inc. (ALT)
- Previous Close
5.25 - Open
5.25 - Bid 3.83 x 200
- Ask 6.52 x 200
- Day's Range
5.07 - 5.36 - 52 Week Range
3.55 - 11.16 - Volume
1,518,884 - Avg. Volume
2,467,883 - Market Cap (intraday)
395.85M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-1.34 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 20, 2017
- 1y Target Est
22.38
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.
altimmune.comRecent News: ALT
View More
Performance Overview: ALT
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALT
View MoreValuation Measures
Market Cap
404.32M
Enterprise Value
274.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.64k
Price/Book (mrq)
3.27
Enterprise Value/Revenue
13.71k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.85%
Return on Equity (ttm)
-59.86%
Revenue (ttm)
20k
Net Income Avi to Common (ttm)
-95.06M
Diluted EPS (ttm)
-1.34
Balance Sheet and Cash Flow
Total Cash (mrq)
131.89M
Total Debt/Equity (mrq)
1.36%
Levered Free Cash Flow (ttm)
-44.87M